IntelGenx Technologies Corp.

CVE: IGX


Canadian symbol: IGX.V
US symbol: IGXT

Currency in CAD

Valuation Measures

Market Cap (intraday) 576.37M
Enterprise Value 386.01M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)49.46
Price/Book (mrq)N/A
Enterprise Value/Revenue 355.71
Enterprise Value/EBITDA 7-15.55

Trading Information

Stock Price History

Beta (5Y Monthly) 2.71
52-Week Change 3150.00%
S&P500 52-Week Change 343.61%
52 Week High 30.8500
52 Week Low 30.1700
50-Day Moving Average 30.6366
200-Day Moving Average 30.4088

Share Statistics

Avg Vol (3 month) 392.97k
Avg Vol (10 day) 3110.47k
Shares Outstanding 5111.91M
Implied Shares Outstanding 6N/A
Float 73.25M
% Held by Insiders 134.63%
% Held by Institutions 10.00%
Shares Short (Apr. 29, 2021) 4197.31k
Short Ratio (Apr. 29, 2021) 41.5
Short % of Float (Apr. 29, 2021) 40.20%
Short % of Shares Outstanding (Apr. 29, 2021) 40.18%
Shares Short (prior month Mar. 30, 2021) 4103.67k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Dec. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-405.70%

Management Effectiveness

Return on Assets (ttm)-35.37%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)1.54M
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)1,061.80%
Gross Profit (ttm)1.54M
EBITDA -5.53M
Net Income Avi to Common (ttm)-7.04M
Diluted EPS (ttm)-0.0790
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.24M
Total Cash Per Share (mrq)0.02
Total Debt (mrq)9.92M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.99
Book Value Per Share (mrq)-0.01

Cash Flow Statement

Operating Cash Flow (ttm)-5.77M
Levered Free Cash Flow (ttm)-4.54M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date

Currency in CAD
Earnings EstimateCurrent Qtr. (Dec 2018)Next Qtr. (Mar 2019)Current Year (2018)Next Year (2019)
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPS-0.02-0.03N/AN/A
Revenue EstimateCurrent Qtr. (Dec 2018)Next Qtr. (Mar 2019)Current Year (2018)Next Year (2019)
No. of Analysts1111
Avg. Estimate200k1.2M1.37M7.36M
Low Estimate200k1.2M1.37M7.36M
High Estimate200k1.2M1.37M7.36M
Year Ago Sales1.46M239k5.2M1.37M
Sales Growth (year/est)-86.30%402.10%-73.60%437.20%
Earnings History2017-12-302018-03-302018-06-292018-09-29
EPS Est.-0.01-0.02-0.04-0.03
EPS Actual-0.02-0.03-0.04-0.04
Difference-0.01-0.010-0.01
Surprise %-100.00%-50.00%0.00%-33.30%
EPS TrendCurrent Qtr. (Dec 2018)Next Qtr. (Mar 2019)Current Year (2018)Next Year (2019)
Current Estimate0000
7 Days Ago-0.04-0.03-0.14-0.1
30 Days Ago-0.04-0.03-0.14-0.1
60 Days Ago-0.04-0.03-0.14-0.1
90 Days Ago-0.04-0.03-0.14-0.1
EPS RevisionsCurrent Qtr. (Dec 2018)Next Qtr. (Mar 2019)Current Year (2018)Next Year (2019)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesIGX.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
34.63%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.01%% of Float Held by Institutions
1Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by IntelGenx Technologies Corp.


IntelGenx Appoints Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel

SAINT LAURENT, Quebec, Jan. 12, 2021 -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (“IntelGenx” or the “Company”) today announced that its Board of Directors appointed Mr. Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel of IntelGenx Corp., the Company’s operating subsidiary. Mr. Kenny ha... Read More...

IntelGenx Receives First Purchase Order For CBD Filmstrips From Heritage Cannabis

SAINT LAURENT, Quebec, Jan. 07, 2021 -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) ("Company" or "IntelGenx") today announced the execution of a definitive supply agreement (the “Agreement”) with Heritage Cannabis Holdings (“Heritage”), an international medical cannabis licensed producer based in Toronto, Canada (CSE:CANN)(OTCMRKTS:HERTF), f... Read More...

IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

SAINT-LAURENT, Quebec, Dec. 08, 2020 -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 899,940 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.335 per Common Share in payment of an aggregate of $301,480 in interest owing on the Cor... Read More...

IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

- Data Suggest Montelukast May Inhibit Mental Decline, Higher Doses Optimal for Clinical Trials Assessing Impact on Neurological Disease -SAINT LAURENT, Quebec, Nov. 09, 2020 -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the peer-reviewed journal, International Journal of Clinical Pharmacy,... Read More...

IntelGenx to Report Third Quarter 2020 Financial Results on November 12, 2020 – Conference Call to Follow

SAINT LAURENT, Quebec, Nov. 05, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its third quarter 2020 financial results after market close on Thursday, November 12, 2020.An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, P... Read More...

IntelGenx Signs Letter of Intent with Heritage Cannabis for Long-Term Cannabis Filmstrip Supply Agreement

SAINT LAURENT, Quebec, Oct. 29, 2020 -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has executed a binding letter of intent (“LOI”) with Heritage Cannabis Holdings Corp. (“Heritage”), an international medical cannabis licensed producer based in Toronto, Canada (CSE:CANN)(OTCQX:HERTF), for... Read More...

IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol

SAINT LAURENT, Quebec, Oct. 21, 2020 -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into an amended and restated license agreement (the “Agreement”) granting Tetra Bio-Pharma (TSX:TBP)(OTCQB:TBPMF)(“Tetra”), a leader in cannabinoid-derived drug discovery and development, addit... Read More...

IntelGenx Closes U.S.$1.2 Million Private Placement Financing

SAINT LAURENT, Quebec, Oct. 15, 2020 -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces the closing of an offering by way of private placement (the “Offering”) to certain investors in the United States of U.S.$1.2 million principal amount of 8% convertible notes due October 15, 2024 (the “Not... Read More...

IntelGenx and Tilray® Agree to Amend Certain Exclusivity Terms of Worldwide Cannabis-Infused VersaFilm® Agreement

SAINT LAURENT, Quebec, July 20, 2020 -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray, Inc. (“Tilray®”) have amended the exclusivity terms of their November 2018 license, development and supply agreement (the “Agreement”) to allow for IntelGenx’s co-development and commercializat... Read More...

IntelGenx Reports Amendment of Stock Option Plan

SAINT LAURENT, Quebec, July 15, 2020 -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) reported today, that the Company's Board of Directors approved an amendment to the Amended 2016 Stock Option Plan (the “Plan”) to increase the number of shares available for issuances under the Plan by 1,678,218 f... Read More...

IntelGenx and Cybin Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

SAINT LAURENT, Quebec, July 07, 2020 -- IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, is pleased to announce that it has entered into a feasibility agreement with Cybin Corp. (“Cybin”), Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derive... Read More...

IntelGenx Announces Approval of Proposed Amendments to Convertible Debentures

SAINT LAURENT, Quebec, June 25, 2020 -- IntelGenx Technologies Corp. (IGX.V) (IGXT) (“IntelGenx” or the “Corporation”) today announced that the holders (“Debentureholders”) of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally issued on July 12, 2017 and August 8, 2017 (the “Debentures”), have approved th... Read More...

IntelGenx Provides Update on RIZAPORT® VersaFilm® NDA Resubmission Process Following Type A Meeting with the FDA

SAINT LAURENT, Quebec, June 11, 2020 -- Saint Laurent, Quebec, June 11, 2020 – IntelGenx Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx") today provided an update regarding its RIZAPORT® VersaFilm® program following its Type A meeting with the U.S. Food & Drug Administration ("FDA") that took place on June 10, 2020.On March 27, ... Read More...

IntelGenx Poised to Launch Hand Sanitizer Business Following Receipt of Health Canada Authorization for Commercial Sale

First Purchase Order Received, with Product Availability Expected by early Q3-2020SAINT LAURENT, Quebec, June 10, 2020 -- IntelGenx Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx") today announced that Health Canada has authorized the sale of IntelGenx’s hand sanitizer product, both in liquid and gel formulations, which will be manu... Read More...

IntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of Debentureholders

SAINT LAURENT, Quebec, May 28, 2020 -- IntelGenx Technologies Corp. (IGX.V) (IGXT) (“IntelGenx” or the “Corporation”) today announced that it intends to issue shares of common stock (“Common Shares”) of the Corporation in payment of the outstanding $7,577,000 aggregate principal amount of the Corporation’s 8.00% convertible unsecured subo... Read More...

IntelGenx to Report First Quarter 2020 Financial Results on May 14, 2020 – Conference Call to Follow

SAINT LAURENT, Quebec, May 08, 2020 -- IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2020 financial results after market close on May 14, 2020.An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre... Read More...

IntelGenx Announces Adjusted VersaFilm® Business Strategy, Next Steps for RIZAPORT® VersaFilm® Program

SAINT LAURENT, Quebec, April 06, 2020 -- IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response Letter (“CRL”) that it recently received from the U.S. Food... Read More...

Intelgenx To Report Fourth Quarter And Full-year 2019 Financial Results On March 26; Conference Call To Follow On March 27

SAINT LAURENT, Quebec, March 23, 2020 -- IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full-year 2019 financial results before market open on Thursday, March 26, 2020.As previously announced, the U.S. Food and Drug Administration has assigned a P... Read More...

IntelGenx Completes C$8.2 Million Equity Offering

SAINT LAURENT, Quebec, Feb. 11, 2020 -- IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 16,317,000 units (the “Units”) at a price of C$0.50 per Unit (the “Offering Price”) for gross proceeds of C$8,158,500.Each Unit consists of one share ... Read More...

IntelGenx Announces Pricing of Equity Offering

SAINT LAURENT, Quebec, Jan. 27, 2020 -- IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of up to 20,000,000 units, subject to a minimum offering of 10,000,000 units (the “Units”), for gross proceeds of between $5,000,000 and $10,000,000, assuming... Read More...

IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

- Ongoing BUENA Trial to Continue at Increased Daily Dose -SAINT LAURENT, Quebec, Jan. 15, 2020 -- IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that Health Canada has issued a No Objection Letter in response to IntelGenx’s amended Clinical Trial Application (“CTA”) for the ongoing Montelu... Read More...

IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

SAINT LAURENT, Quebec, Jan. 13, 2020 -- IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today provided a commercial update on its two lead product candidates, cannabis-infused VersaFilm® and RIZAPORT®. IntelGenx is providing this information ahead of its planned participation in investment community meeting... Read More...

IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

SAINT LAURENT, Quebec, Jan. 09, 2020 -- IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”) a leader in pharmaceutical films, today announced that it has entered into a Feasibility Study Agreement (the “Agreement”) with an undisclosed partner (the “Partner”) focused on bringing innovative animal health products to the market.Pursuant to the Agre... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
Horst G. Zerbe
Chairman of the Board, Chief Executive Officer
73Chairman of the Board, Chief Executive Officer2019
Andre Godin
President, Chief Financial Officer
57President, Chief Financial Officer2019
J. Bernard Boudreau
Independent Vice Chairman of the Board
75Independent Vice Chairman of the Board2014
Rodolphe Obeid
Vice President - Operations
40Vice President - Operations2019
Tommy Kenny
Vice President - Intellectual Property and Legal Affairs, General Counsel
--Vice President - Intellectual Property and Legal Affairs, General Counsel2021
Dana Matzen
Vice President - Business and Corporate Development
42Vice President - Business and Corporate Development2016
Nadine Paiement
Vice President - Research & Development
43Vice President - Research & Development2016
Ingrid Zerbe
Corporate Secretary
64Corporate Secretary2016
John Marinucci
Independent Director
63Independent Director2010
Clemens Mayr
Independent Director
52Independent Director2015
Bernd J. Melchers
Independent Director
68Independent Director2009
Mark H. Nawacki
Independent Director
51Independent Director2016


Share this page